Following successful trials at extracranial sites, increased efficacy has been demonstrated in the brain from combined ICI with PD-1/CTLA-4 blockade with response rates approaching 50% in these selective cohorts of patients with melanoma BrM, with some patients achieving a complete response [18, 19]. The gene discussed is CTLA4; the disease is melanoma.